|
|
Post by uvula on Jan 17, 2023 11:53:48 GMT -5
|
|
|
|
Post by longliner on Jan 17, 2023 11:59:31 GMT -5
The pediatric trials will move the needle. What child (or parent) would begin with less (or no injections) then opt for slower speed and needles? They will still need a daily basal injection with Afrezza, but it does avoid the four or so other injections. The competition isn't MDI, it's automated insulin delivery pumps. These are being very heavily pushed right now because something like the 780G is averaging out at a TIR of 74% in the real world. Endos really like that, and having kids on them reduces the need for the parents and kid to manage things which always helps. That TIR is better than Afrezza has achieved in trials so far. Fortunately, the Afrezza pediatric trial is underway. Once the trial results are published we will have verifiable numbers to actually compare Afrezza to everything else. |
|
|
|
Post by oldfishtowner on Jan 17, 2023 12:29:00 GMT -5
Can I guess the 125,000 between 2016 - 2020 is wrong as well? Reason being it seems strange MC would discount 2021 and 2022 in his total. Covered only through 2020 because he was using liane's original script chart to find total scripts?  |
|
|
|
Post by oldfishtowner on Jan 17, 2023 12:44:27 GMT -5
Is mc bragging about the horrible retention rate? Only 1% of the people who tried it are still using it. I think you are off by a factor of 10. But then, Castagna is not much better. Even if the average weekly script total was 800, which it was not, the total for 2021 and 2022 would only be 800 x 104 = 83,200. It takes pretty generous rounding up to get 100,000. Normally the number would have been rounded down to 80,000 (if rounded to one significant figure, which is what Castagna did). |
|
